yeah I'm well aware of that but that's contingent on all those things happening before they run out of cash which will be in the next 3 months. Even then, TGA approval won't bring in cash immediately. Angelmed guardian won't be profitable in APAC region for at least few years after TGA approval is granted. Hydrix's service division might have built up the sales pipeline to pre-COVID level so they might be able to come close to positive cashflow. That's the only way I see they can go another quarter without CR. It's important they recover the share price to 12c so those options can be exercised and bring much needed cash infusion to the company.
HYD Price at posting:
9.5¢ Sentiment: None Disclosure: Held
